Risk of Rash Associated With Lenalidomide in Cancer Patients: A Systematic Review of the Literature and Meta-analysis

Abstract Background Lenalidomideis indicated for treatment of multiple myeloma in combination with dexamethasone and as a single agent in myelodysplastic syndromes. The incidence and risk of rashhas been inconsistently reported. Materials and Methods We conducted a systematic review and metaanalysis of the literature to determine the incidence and risk of developing rash. Relevant studies were identified from PubMed and abstracts presented at American Society of Clinical Oncologyannual meetings. Incidence, relative risk, and 95% confidence intervals were calculated. Results Ten trials were available for analysis, and the overall incidence of all-grade and high-grade rashwas 27.2% and 3.6%, respectively. Lenalidomidewas associated with increased risk of all-grade rash( P Conclusion Further studies for prevention and treatment of this toxicity are needed to minimize effect on quality of life and dose intensity.